KCNN4 and sickle cell disease: Senicapoc, a new and more potent inhibitor of KCa3.1, has been tested in clinical trials for sickle cell anemia and is shown to be safe and well tolerated in patients, offering a faster option for treatment of muco-obstructive diseases in humans (63).